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Cancer is one of the most devastating diseases and a leading cause
of death in the world. According to the mortality data from the
National Center for Health Statistics in 2013, one in four deaths in
the United States is due to cancer1. Chemotherapy is a treatment
choice for many types of cancers, but its success is often hampered
by development of drug resistance after repeated administration.
Drug resistance has a genetic basis and it is caused by abnormal
gene expression. There are several types of drug resistance,
including efﬂux pumps which reduce the cellular concentration
of the drug, alterations in membrane lipids that reduce cellular
uptake, increased or altered drug targets, metabolic alteration of
the drug, inhibition of apoptosis, repair of the damaged DNA, and
the alteration of cell cycle checkpoints2–5.
RNA interference (RNAi) is a special mechanism which occurs
normally in most eukaryotic cells. RNAi mediated by small
interfering RNA (siRNA) and microRNA (miRNA) have emerged
as the most promising strategies for anti-cancer therapy, since
siRNA and miRNA can induce gene-speciﬁc cleavage through
their complementary pairing with mRNA, resulting in degradation
of mRNA. For example, siRNA targeting the MDR1 gene can
reduce the formation of efﬂux transporters in cell membrane,
resulting in an increase in cellular drug concentration6. Survivin
siRNA can sensitize the drug resistance cells by inhibiting cell
survival pathway7. Therefore, the silencing of the gene will open a
window of time in which the resistant cells transiently become
sensitized to the anti-cancer drug, thereby overcoming multi-drug
resistance8–11. On the other hand, since tumor suppressor protein
gene, such as p53, can induce cell growth arrest or apoptosis,
plasmid DNA encoding p53 can also be delivered for cancer
therapy. All the RNA interference agents and plasmid DNA are
known as gene agents12.
Combination therapy is emerging as a promising approach for
the treatment of cancer. Rational drug combinations aim to exploit
either additive or synergistic effects arising from the action of
several species with the ﬁnal goal to maximize therapeutic
efﬁcacy. It has been shown that an appropriate combination of
chemotherapeutic drugs and gene agents can improve the thera-
peutic outcome and patient compliance due to reduced dose and
decreased development of drug resistance13,14.
However, the biggest challenge in co-delivery drugs and gene
agents is to ﬁnd applicable carriers, since gene agents have higher
molecular weight and negatively charged surface, while most
frequently used anti-cancer drugs are hydrophobic small mole-
cules15. During the recent years, there has been a remarkable
progress in a co-delivery system. The objective of this article is to
review various nanocarriers that have been researched for the co-
delivery of chemotherapeutic drugs and gene agents for tumor
therapy, and to make suggestions for further design the in co-
delivery system.2. Co-delivery nanocarriers for drugs and gene agents
Since the physicochemical properties of oligonucleotides are
drastically different from those of small molecular weight drugs,
separate mechanisms are usually required to encapsulate these two
distinct payloads. The small-molecule drugs can be enclosed
within the nanocarriers via hydrophobic force, electrostatic inter-
action or chemical conjugation, whereas gene agents are usually
compressed by the carriers through electrostatic force15. To meetthe above requirements, traditional nanocarriers, such as liposome
and micelle, and novel nanocarriers, including dendrimer and a
supramolecular system, have been used to delivery chemothera-
peutic drugs and gene agents, as demonstrated in Table 16,7,16–39
and 240–60. The following section will systematically review the
commonly and recently employed organic nanocarriers for the co-
delivery of gene agents and drugs.
2.1. Traditional nanocarrier
2.1.1. Liposome-based nanocarrier
Liposomes represent one of the most successful drug vehicles, as
well as in the co-delivery of chemotherapeutic drugs and gene
agents. Recently, many researchers reported their achievements in
co-delivery systems using modiﬁed cationic liposomes, as shown
in Table 1. 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP)
is the most commonly utilized cationic lipid21. Cationic liposome-
based nanoformulations are usually prepared through simple
electrostatic interaction between the positively charged cationic
lipids and the negatively charged phosphate backbones of oligo-
nucleotides. The drugs can be loaded via hydrophobic force, as
exhibited in Fig. 1a. However, the liposome usually has poor
physiological stability compared to other polymeric vectors13.
Saad and colleagues19 demonstrated a cationic liposome-based co-
delivery system, which consisted of cationic lipids, doxorubicin, and
siRNA targeted to MRP1 and BCL2 mRNA (suppressors of pump
and nonpump cellular resistance, respectively). The drug vehicle
provided an effective co-delivery approach to induce cell death and to
suppress cellular resistance in MDR lung cancer cells. Sun and
colleagues17 reported an angiopep-2 modiﬁed cationic liposome
(ANG-CLP) for the efﬁcient co-delivery of a therapeutic gene
encoding the human tumor necrosis factor-related apoptosis-inducing
ligand (pEGFP-hTRAIL) and paclitaxel for glioma. The dual targeting
co-delivery system improved uptake and gene expression not only in
U87 MG cells and BCECs, but also in the glioma bed and inﬁltrating
margin of intracranial U87 MG glioma-bearing models.
To improve tumor therapy efﬁcacy, Feng and colleagues20 built a
vapreotide-modiﬁed core-shell type nanoparticle co-encapsulating
VEGF-targeted siRNA (siVEGF) and paclitaxel. Vapreotide is a
somatostatin analog possessing high afﬁnity to somatostatin receptors
(SSTRs), which are overexpressed in many tumor cells. The
nanoparticle core was a negatively charged ternary complex com-
posed of siRNA, chondroitin sulfate and protamine, and could be
coated with cationic lipid shell. As a result, the mixed liposome had
signiﬁcantly stronger drug distribution in tumor tissues via receptor-
mediated targeting delivery, accompanied by substantial inhibition of
neovascularization induced by siVEGF silencing.
2.1.2. Micelle based nanocarrier
To achieve simultaneous delivery of chemotherapeutic drugs and
gene agents, the carriers must be able to protect the contents from
degradation and prevent premature release. Micelleplexes consist-
ing of amphiphilic block copolymers are the most commonly
reported examples of co-delivery carriers, as shown in Table 1.
Usually, the micelle self-assembles with the hydrophobic blocks to
form the interior of the micelle and with hydrophilic blocks to
form the micelle shell61. The hydrophobic interior acts as a
reservoir for the poorly soluble hydrophobic drugs. Hydrophilic
blocks on the shell mask the payloads. The most frequently used
mask is polyethyleneglycol (PEG). Other commonly-used hydro-
philic blocks are cationic polymers that can condense/complex
Table 1 Traditional co-delivery nanocarriers of chemotherapeutic drugs and gene agents in recent researches.
Carrier type Composition of carrier Drug Gene agent Cell line Ref.
Cationic liposome Cationic solid lipid nanoparticles (cSLN) Paclitaxel MCL1 siRNA KB 16
Angiopep-2 modiﬁed cationic liposome Paclitaxel pEGFP-hTRAIL U87 17
PLGA/FPL Doxorubicin pEGFP MDA-MB-231 18
Cationic liposome Doxorubicin MRP1 and BCL2 siRNA MCF-7, HCT15 19
Vapreotide-modiﬁed core–shell liposome Paclitaxel VEGF siRNA MCF-7 20
Lipid nanocapsules functionalized with
PEI
Paclitaxel pDNA HEK 21
Thermosensitivemagneticcationic
liposomes
Doxorubicin SATB1 shRNA MKN-28 22
Nanostructured lipid carrier Doxorubicin
or paclitaxel
MRP1 and BCL2 siRNA A549 23
PEGylated liposome Docetaxel BCL2 siRNA A549 24
Micelle Amphiphilic chimeric peptide
(Fmoc)2KH7-TAT
Doxorubicin p53 plasmid 293T, Hela 25
PEG-PAsp(AED)-PDPA Doxorubicin BCL2 siRNA SKOV-3 26
PEI-PCHLG Docetaxel pDNA HEK293 27
PDMAEMA-PCL-PDMAEMA Paclitaxel GFP siRNA MDA-MB-435 28
P85-PEI/TPGS Paclitaxel Survivin shRNA A549 29
ABP-PEG3.5k-paclitaxel Paclitaxel gWiz-Luci MCF-7, A549
30
FA-PEG-PGA and PEI-PCL Doxorubicin BCL2 siRNA C6 31
FA-PEG-PGA and PEI-PCL Doxorubicin BCL2 siRNA Bel-7402 32
PEO-b-PCL Doxorubicin MDR1 siRNA MDA-MB-435 6
Oligopeptide amphiphile Doxorubicin Luc siRNA HepG2 33
PDP-PDHA Doxorubicin Surviving shRNA MCF-7 34
PEG-pp-PEI-PE Paclitaxel Surviving siRNA A549 7
MPEG-PCL-g-PEI Doxorubicin Msurvivin T34A gene B16F10, MCF-7,
CT26
35
PEOz-PLA-g-PEI Doxorubicin mcDNA MCF-7 36
PEG-PLL-PLLeu Docetaxel BCL2 siRNA MCF-7 37
Cationic core-shell nanoparticles Paclitaxel IL-2 plasmid BCL2 siRNA MDA-MB-231,
4T1
38
mPEG45-b-PCL80-b-PPEEA10 Paclitaxel polo-likekinase 1 (Plk1)
speciﬁc siRNA
MDA-MB-435 39
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and poly(2-aminoethyl ethylene phosphate) (PPEEA) are the most
frequently used cationic blocks. The most popular hydrophobic
polymers are poly(ε-caprolactone) (PCL), poly(n-butyl acrylate)
(PnBA), polylactide (PLA) and poly(lactic-co-glycolic acid)
(PLGA). The outer shell may be further decorated with targeting
ligands, such as folate, to enhance the active targeting-ability of the
carrier in most cases13, as exhibited in Fig. 1b. Micelle-based
nanocarriers are tunable, biocompatible, and physiologically stable
owing to their low critical micelle concentration (CMC); the prepara-
tion process of functional block polymers is always complicated13.
Zhu and co-workers28 prepared a biodegradable cationic micelle
with PDMAEMA-PCL-PDMAEMA triblock copolymer, which
formed nano-sized micelles in water with positively charged
surface that could be applied for the delivery of VEGF siRNA
and paclitaxel. Cao and colleagues32 synthesized a diblock
copolymer consisted of linear poly(ethyleneimine) and poly(ε-
caprolactone) (PEI-PCL), and the amphiphilic polymer assembled
into micelles for co-delivery of BCL2 siRNA and doxorubicin.
Folic acid was conjugated to the polyanion and further coated onto
the surface of the cationic PEI-PCL nanoparticle pre-loaded with
siRNA and doxorubicin, potentiating a ligand-directed delivery to
human hepatic cancer cells. This hierarchical assembly strategy
was beneﬁcial for active targeting. Another dual-functional
poly(ethyleneimine)-poly(γ-cholesterol-L-glutamate)(PEI-PCHLG)copolymer was synthesized by Zhang et al.27 for the co-delivery.
PCHLG played an analogous role to lipoproteins in terms of drug
delivery, and had high drug loading. PEI-PCHLG was able to
assemble into micelles with high drug and gene loading efﬁciency.
Amphiphilic chimeric peptide, for example, (Fmoc)2KH7-TAT
25
and Ac-(AF)6-H5-K15-NH2(FA32)
33, can also be used for drug and
gene co-delivery.
Stimuli-responsive micelle systems have also been developed for
co-delivery. Zhu et al.7 presented a simple but multifunctional
micellar platform constructed by a matrix metalloproteinase 2
(MMP2)–sensitive copolymer (PEG-pp-PEI-PE) via self-assembly
for tumor-targeted siRNA and drug co-delivery. The unique delivery
system exhibited excellent stability and tumor-targeting triggered by
the up-regulated tumoral MMP2. This system achieves enhanced cell
internalization after MMP2-activated exposure of the previously
hidden PEI. Chen et al.26 developed a reduction and pH dual-
sensitive nanocarrier for synergistic cancer therapy. A ternary block
copolymer PEG-PAsp(AED)-PDPA contained pH-sensitive poly(2-
(diisopropyl amino)ethyl methacrylate) (PDPA), reduction-sensitive
poly(N-(2,20-dithiobis(ethylamine))aspartamide) (PAsp(AED)) and
PEG. The copolymer assembled into a core–shell structural micelle,
which encapsulated doxorubicin in its pH-sensitive core and BCL2
siRNA in a reduction sensitive interlayer. The dual stimuli-responsive
design of micellar carrier allowed microenviroment-speciﬁc rapid
release of both doxorubicin and BCL2 siRNA inside acidic
Figure 1 Schematic illustration of four major types of nanocarriers to co-delivery gene and chemotherapeutic drug. (a) Cationic liposome,
the most frequently used cationic lipid and general lipid are DOTAP and DOPE, respectively, and PEG modiﬁed with PE can prolong the cycle
time in the circulation system. (b) Micelle system, hydrophilic block is usually positively charged, such as PEI, polyamino acid and so on,
PCL, PLA and PE are employed as hydrophobic core. (c) Dendrimer system, PAMAM is the most commonly used dendrimer for co-delivery.
(d) A supramolecular system, γ-CD can form inclusion complexes with chemotherapeutic drugs.
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tically-enhanced apoptosis of human ovarian cancer SKOV-3 cells,
thereby dramatically inhibiting tumor growth.2.2. Non-traditional nanocarrier
2.2.1. Dendrimer based nanocarrier
Dendrimers are hyperbranched and monodispersed macromole-
cules which have deﬁned molecular weights and host–guest
entrapment properties. More importantly, dendrimers can interact
with drug and gene molecules by simple encapsulations, electro-
static interactions and covalent conjugations since they possess
empty internal cavities and a much higher density of surface
functional group62, as shown in Fig. 1c. Therefore, monodispersal
and high drug-loading capacity are prominent advantages of
dendrimers. However, dendrimers still have some safety–toxicity
issues according to comprehensive statistics14.
Several polyamine polymers have been explored as carriers for
drug delivery. For example, poly(amido amine) (PAMAM), a
cationic dendrimer which introduces ammonia as the core, has
been investigated as non-viral delivery vector for efﬁcient siRNA
delivery63. Han and co-workers41 employed peptide HAIYPRH
(T7)-conjugated PEG-modiﬁed PAMAM dendrimer (PAMAM-
PEG-T7) for the co-delivery of pDNA and doxorubicin. In
comparison with single doxorubicin or pDNA delivery system,
this co-delivery system induced apoptosis of tumor cells in vitro
and inhibited tumor growth in vivo more efﬁciently. Combining
PAMAM with other amphiphilic block copolymers was also an
approach for co-delivery. Biswas et al.46 modiﬁed PAMAM with
poly(ethyleneglycol)-1,2-dioleoyl-sn-glycero-3-phospho-ethanol-
amine to form a new construct G(4)-D-PEG-2K-DOPE. This G(4)-
PAMAM dendrimer was utilized as a cationic source for efﬁcient
siRNA condensation; DOPE provided optimum hydrophobicity
and compatible cellular interaction for enhanced cell penetration.
PEG rendered ﬂexibility to the G(4)-D for easy accessibility of
siRNA for condensation. This nanocarrier formed stable poly-
plexes with siRNA, showed a signiﬁcantly higher cellular uptakeof siRNA, excellent serum stability and efﬁcient micellization, and
higher doxorubicin-loading efﬁciency.
Except for PAMAM, dendrimer analogs have also been investi-
gated in drug and gene co-delivery. Liu et al.42 prepared a new
cyclodextrin derivative (CD-PLLD) consisted of a β-cyclodextrin
core and poly(L-lysine) dendron arms for doxorubicin and MMP-9
siRNA plasmid co-delivery. Qian et al.43 constructed dendrimer
analogs with three amphiphilic star-branched copolymers comprising
polylactic acid (PLA) and polydimethylaminoethyl methacrylate
(PDMAEMA) for microRNA and doxorubicin transport. By testing
architectures with different repeat degrees, they found that (AB3)3
architecture exhibited the highest transfection efﬁciency. Ma and
colleagues44 designed a star-shaped porphyrin-arginine-functionalized
poly(L-lysine) copolymer (PP-PLLD-Arg) for photo-enhanced drug
and gene co-delivery. Results with this copolymer demonstrated that
PP-PLLD-Arg with suited irradiation was a promising non-toxic and
photo-inducible effective drug and gene delivery strategy.2.2.2. Supramolecular nanocarrier
The development of self-assembly techniques has permitted the
introduction of supramolecular nanoparticles (SNPs), such as
host-guest architectures, as drug and non-viral gene carriers. The
host-guest system is a complex in which one chemical compound
(the “host”) forms a cavity in which molecules of a second “guest”
compound are located. In drug delivery system, the most
frequently used host is γ-cyclodextrin (γ-CD), which contains a
torus-like structure with a hydrophobic cavity, and can form
inclusion complexes with chemotherapeutic drug, as demonstrated
in Fig. 1d. Rational inclusion complexes exhibit excellent serum
stability and promising application. However, perfectly matched
host/guest materials are not easy to ﬁnd.
Recently, Yang and colleagues49 designed a pH-responsive
drug/gene co-delivery nanoplatform by means of host–guest
chemistry. γ-CD/doxorubicin complexes were attached onto
phenylboronic-acid-modiﬁed oligoethylenimine (PEI1.8K-PB2.9) at
neutral conditions. The drug is detached from PEI1.8K-PB2.9
under acidic conditions owing to the acidity-labile feature of
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PEI1.8K-PB2.9-γ-CD conjugates demonstrated signiﬁcantly
improved cell-biocompatibility and DNA transfection activity by
overcoming serum-susceptible drawbacks frequently associated
with synthetic gene carriers. Zhao and co-workers12 also employed
γ-CD and multiple oligoethylenimine (OEI) arms with folic acid
(FA) as co-delivery materials for paclitaxel and pDNA.
In another study, Fan and colleagues48 designed a SNP
consisted of host PEI-CD (as gene vector) and guest adamantane
conjugated groups (as chemotherapeutic agent carriers) for co-
delivery of drug and gene. The adamantane-conjugated doxorubi-
cin as the guest Ad-Dox component assembled with the host PEI-
CD into supramolecular PEI-CD/Ad-Dox, which could further
interact with plasmid DNA to form drug- and gene-loaded PEI-
CD/Ad-Dox/pDNA SNP. The in vitro data in different cell lines
indicated that such SNP could ensure that both drug and gene can
be delivered to the same cancer cell, providing the feasibility of
combinational tumor treatment. Hu et al.47 conducted synergistic
treatment of ovarian cancer by co-delivery of survivin shRNA and
paclitaxel via a similar supramolecular micellar assembly.
2.2.3. Novel nanoformulation
Chang et al.50 constructed a redox-responsive system for drug/siRNA
co-delivery based on ferrocenium capped amphiphilic pillar[5]arene
(FCAP). Pillar[n]arenes are a new class of macrocyclic compounds
which possess a hydrophobic core sandwiched between two functional
rims and can self-assemble to cationic vesicles in aqueous solution. The
ferrocenium cation, which is sensitive to glutathione (GSH), is a redox-
responsive bond, and the positive charge of ferrocenium makes
possible for the loading of negatively charged siRNA ontoTable 2 Non-traditional co-delivery nanocarriers of chemotherapeut
Carrier type Composition of carrier
Dendrimer T7-modiﬁed dendrigraftpoly-L-lysine
PAMAM-PEG-T7
b-cyclodextrin core and poly(L-lysine) dendron
PLA-b-PDMAEMA
Porphyrin-arginine Functionalized poly(L-lysine
copolymer
Poly(L-lysine) dendrimers with a silsesquioxane
cubic core
G(4)-D-PEG-2K-DOPE
Supramolecular system Host PEI-CyD (PC) guest adamantine conjugate
PTX
Host PEI-CyD (PC) guest adamantine conjugate
DOX
β-CD and OEI-FA
PEI1.8k–PB2.9–γ-CD
Novel nanoformution Amphiphilicpillar[5]arene capped with ferrocen
Aptamerconjugated PEI-PEG
Chitosan-graft-PEI
Hyaluronic acid and chitosan
Layered double hydroxide
CholsiRNA/LDL-coupled N-succinyl chitosan
PEG-Pep-PCL copolymer
PLGA nanoformulation
PEI-Fc
Cationic polymeric nanocapsules
PEI-PEG based nanoparticlesnanocarriers. Therefore, FCAP allowed building an ideal GSH-
responsive drug/siRNA co-delivery system for rapid drug release and
gene transfection in cancer cells in which higher GSH concentration
existed.
Chen et al.59 reported a unique architecture, cationic polymeric
nanocapsule, which had well-deﬁned covalently stabilized biodegrad-
able structures and can function as a potentially universal and safe
therapeutic nanocarrier for co-delivery of doxorubicin and siRNA
targeting interleukin-8. This nanocapsule was synthesized from allyl-
functionalized cationic polylactide (CPLA) by a highly efﬁcient UV-
induced thiol-ene interfacial cross-linking in transparent miniemul-
sions. Liu and co-workers56 adopted a double-emulsion solvent
evaporation technique to prepare intelligent gelatinases-stimuli nano-
particles for the co-delivery of miR-200c and docetaxel. This
miniemulsion was able to inhibit cancer stem cells and non-cancer
stem cells and showed promise for cancer therapy.
Dr. Hammond's group64 developed a layer by layer nanoplat-
form for systemic co-delivery of doxorubicin and siRNA for
potential triple-negative breast cancer treatment. The layer by layer
nanoparticle could be divided into three parts in structure: drug-
loaded core, siRNA/polycation–loaded middle ﬁlm and tumor
targeting outer shell. The advantage of this unique architecture was
that it provided a modular platform for a broad range of controlled
multidrug therapies customizable to the cancer type in a singular
nanoparticle delivery system. Meanwhile, Sun et al.58 presented a
system with multilayers for co-delivery of doxorubicin and DNA.
Ferrocene modiﬁed poly(ethyleneimine) (PEI-Fc) formed micelles
in solution and trapped DNA and drug to form PEI-Fc–DOX-DNA
nanocomplexes, and such cationic nanocomplexes were further
used to construct multilayers through layer by layer assembly withic drugs and gene agents in recent researches.
Drug Gene agent Cell line Ref.
Doxorubicin pTRAIL U87 40
Doxorubicin pORF-hTRAIL Bel-7402 41
arms Docetaxel pMR3 HNE-1 42
Doxorubicin miR-21 LN229 43
) Docetaxel MMP-9 shRNA HNE-1 44
Doxorubicin luciferase siRNA U87 45
Doxorubicin siGFP A549 46
d Paclitaxel Survivin shRNA SKOV3 46
d Doxorubicin pTRAIL SKOV3 48
Paclitaxel p53 KB, A549 12
Doxorubicin pDNA 293T, HeLa 49
ium Doxorubicin MDR1 siRNA 293T, HeLa 50
Doxorubicin Bcl-xL shRNA PC3, LNCaP 51
Candesartan p53 PANC-1 52
Doxorubicin miR-34a MDA-MB-231 53
5-ﬂuorouracil Allstars Cell
Death siRNA
MCF-7, U2OS
and HCT-116
54
Doxorubicin MDR1 siRNA HepG2 55
Docetaxel miR-200c BGC-823 56
Doxorubicin MDR1 siRNA MCF-7 57
Doxorubicin DNA HepG2 58
Doxorubicin IL-8 siRNA MCF-7 59
Doxorubicin DNA HUVE, HepG2,
MCF-7
60
Lin Kang et al.174negatively charged dextran sulfate. The multilayers could be
potentially applied to the biomedical devices for cancer treatment,
regenerative medicine, etc. Some other novel co-delivery nano-
formulations are displayed in Table 2.3. Conclusions and future perspectives
The co-delivery of chemotherapeutic drugs and gene agents
provides a promising strategy to overcome drug resistance in
cancer therapy. According to recent research, it is clear that
combination delivery of gene and drug using nanocarriers is
indeed helpful in inhibiting tumor growth compared to gene or
drug alone. Although various nanocarriers have been developed
for co-delivery, most carriers just focus on successful co-delivery
of gene and drug. This approach has often resulted in functional
materials, such as PEG, PEI and PLGA et al., being used
repeatedly in different permutation and combination, without
paying attention to the rational ratio of gene and drug or the
interaction between them in the vehicle. Development of new
materials and technologies affords the opportunity to discover and
produce novel drug delivery systems. Presently, an ideal co-
delivery carrier should be biocompatible and biodegradable, and
demonstrate circulatory stability, thereby facilitating transport of
the cargos to the targeting sites. The ideal carrier will also be
multifunctional, with the ability to transport simultaneously both
chemotherapeutic drugs and gene agents to cancer cells, releasing
the payloads in a controlled manner and accurate dose, thereby
achieving a maximum effect of the combination therapy for
treating drug resistant tumors. Further studies should focus on
the interaction between drugs and gene agents, as well as the
interaction between therapeutic agents and carriers. Continuous
development of such combination delivery systems will ultimately
lead toward availability of effective therapies for cancer.
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